{
  "query_term": "TALVEY (talquetamab)",
  "total_count": 5,
  "returned": 5,
  "kept": 4,
  "studies": [
    {
      "nct_id": "NCT05972135",
      "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "SCRI Development Innovations, LLC",
      "collaborators": [
        "Johnson & Johnson"
      ],
      "interventions": [
        "Teclistamab",
        "Talquetamab",
        "Tocilizumab"
      ],
      "last_update": "2025-10-29",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05972135"
    },
    {
      "nct_id": "NCT06285318",
      "title": "A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma (RRMM)"
      ],
      "lead_sponsor": "Janssen-Cilag Ltd.",
      "collaborators": [],
      "interventions": [
        "Teclistamab",
        "Talquetamab"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06285318"
    },
    {
      "nct_id": "NCT07029776",
      "title": "A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma (MM)"
      ],
      "lead_sponsor": "University of Arkansas",
      "collaborators": [
        "Janssen Research & Development, LLC"
      ],
      "interventions": [
        "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance",
        "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy"
      ],
      "last_update": "2025-11-06",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07029776"
    },
    {
      "nct_id": "NCT06208150",
      "title": "A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Talquetamab",
        "Pomalidomide",
        "Teclistamab",
        "Elotuzumab",
        "Dexamethasone",
        "Bortezomib"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06208150"
    }
  ]
}